Merkel cell carcinoma (MCC) is extremely rare. About 3,000 people are diagnosed with it in the United States each year, making it roughly 30 to 40 times less common than melanoma. The incidence rate has held steady since 2013 at around 0.68 per 100,000 person-years, or about 7 cases per million people annually. To put that in perspective, for every MCC diagnosis recorded between 2000 and 2021, there were roughly 33 melanoma diagnoses during the same period.
How MCC Compares to Other Skin Cancers
Melanoma is often described as the most dangerous common skin cancer, with close to 100,000 new U.S. cases per year. MCC is far less common but, case for case, more lethal. A large comparative study covering 2000 through 2021 found that patients with MCC had more than twice the cancer-specific mortality risk of melanoma patients. The overall five-year relative survival rate for MCC across all stages is 69%, compared to roughly 93% for melanoma.
Non-melanoma skin cancers like basal cell and squamous cell carcinoma are astronomically more common, with millions of cases diagnosed annually. MCC occupies a sliver of the skin cancer landscape, but its aggressiveness makes it clinically significant despite its rarity.
Who Gets MCC
MCC overwhelmingly affects older adults. Only about 2% of cases occur in people under 50, and the vast majority are diagnosed well past that threshold. Men are diagnosed at roughly twice the rate of women. Race plays a significant role in risk: among adults 50 and older, non-Hispanic white individuals have an incidence rate of 2.5 per 100,000, compared to 1.1 per 100,000 for Hispanic individuals and 0.3 per 100,000 for non-Hispanic Black individuals. White men over 50 face the highest rate at 3.8 per 100,000.
People with weakened immune systems, including organ transplant recipients and those with HIV or certain blood cancers, face substantially elevated risk. Chronic sun exposure over decades is another major contributor, which helps explain why fair-skinned older men are the most commonly affected group.
What Causes Such a Rare Cancer
About 75% of MCC tumors contain DNA from a common virus called Merkel cell polyomavirus. Most people are exposed to this virus at some point in life without consequence. In rare cases, the virus integrates into skin cell DNA in a way that drives uncontrolled growth. The remaining 20 to 30% of MCC cases don’t involve the virus at all and appear to arise from accumulated ultraviolet radiation damage, similar to the pathway behind other skin cancers.
These two distinct origins mean MCC isn’t a single disease with one cause. Virus-driven and UV-driven tumors have different genetic profiles, though they look similar under a microscope and are treated the same way.
What MCC Looks and Feels Like
MCC typically appears as a firm, painless, dome-shaped bump on sun-exposed skin. It’s often red, pink, or violet and can be mistaken for a cyst or insect bite. Clinicians use the acronym AEIOU to describe its hallmark features: asymptomatic (not tender), expanding rapidly, associated with immune suppression, occurring in someone older than 50, and located on UV-exposed skin in a fair-skinned person. In one study of 195 patients, 89% of primary tumors matched three or more of those criteria.
The most common locations are the head and neck (about 29% of cases) and the upper or lower extremities (about 28%). The trunk accounts for roughly 12%. What makes MCC tricky is that it doesn’t look alarming to most people. The bump grows fast, often doubling in size over weeks, but it rarely hurts or bleeds in the early stages. That rapid, painless growth on a sun-exposed area in an older adult is the combination that should prompt a biopsy.
Survival Rates by Stage
When MCC is caught while still localized to the skin, the five-year relative survival rate is 79%. That drops to 66% when the cancer has spread to nearby lymph nodes (regional stage) and 31% when it has reached distant organs. These numbers are based on patients diagnosed between 2015 and 2021.
Survival has improved in recent years thanks to immunotherapy drugs that help the immune system recognize and attack cancer cells. The comparative study of MCC and melanoma noted that cancer-specific mortality improved for both diseases after 2011, when checkpoint inhibitors entered clinical use. For a cancer this rare, the introduction of effective immunotherapy has been a meaningful shift in outcomes, particularly for advanced-stage patients who previously had very limited options.
Why Rarity Matters for Diagnosis
The biggest practical consequence of MCC’s rarity is that most doctors have never seen a case. General practitioners and even some dermatologists may not consider it when evaluating a new skin lesion. Studies consistently show that MCC is frequently misdiagnosed at first glance, often as a benign cyst or a different type of skin cancer. The average time from when a patient first notices the bump to a correct diagnosis can stretch longer than it should.
If you’re over 50, fair-skinned, and notice a firm, painless, fast-growing bump on skin that gets regular sun exposure, those overlapping features are worth bringing to a dermatologist’s attention specifically. Mentioning the rapid growth is especially important, since that’s the feature that most clearly separates MCC from benign lumps. Early-stage detection makes a significant difference in outcomes for a cancer where the gap between localized and distant survival is nearly 50 percentage points.